Table 5. Heterologous response (A/turkey/Turkey/1/05 − NIBRG-23) following immunisation with MF59-adjuvanted H5N1 subunit influenza vaccine.
Assessment Parameter | 7.5 μg HA | 15 μg HA | |||
Adult | HI | n = 70 | n = 79 | ||
Post-second injection (day 43) | GMT | 18 (13–24) (n = 69) | 14 (10–19) (n = 78) | ||
Seroprotection rate | % | 36 (25–49) | 28 (19–40) | ||
Post-booster injection (day 223) | GMT | 58 (39–86) | 46 (31–67) | ||
Seroprotection rate | % | 70 (58–80) | 59 (48–70) | ||
MN | n = 70 | n = 81 | |||
Post-second injection (day 43) | GMT | 19 (15–24) | 19 (15–24) | ||
Titer ≥40 | % | 27 (17–39) | 21 (13–31) | ||
Post-booster injection (day 223) | GMT | 77 (60–100) | 93 (74–118) | ||
Titer ≥40 | % | 73 (61–83) | 79 (69–87) | ||
SRH | n = 70 | n = 81 | |||
Post-second injection (day 43) | GMA | 23 (19–28) | 24 (20–28) | ||
Seroprotection rate | % | 70 (58–80) | 70 (59–80) | ||
Post-booster injection (day 223) | GMA | 30 (26–36) | 34 (29–39) | ||
Seroprotection rate | % | 83 (72–91) | 88 (78–94) | ||
Elderly | HI | n = 36 | n = 26 | ||
Post-second injection (day 43) | GMT | 14 (8.4–22) | 13 (7.74–23) (N = 23) | ||
Seroprotection rate | % | 36 (21–54) | 35 (16–57) | ||
Post-booster injection (day 223) | GMT | 36 (19–68) | 49 (25–97) | ||
Seroprotection rate | % | 67 (49–81) | 65 (44–83) | ||
MN | n = 37 | n = 26 | |||
Post-second injection (day 43) | GMT | 12 (9.4–16) | 17 (13–23) | ||
Titer ≥40 | % | 11 (3–25) | 31 (14–52) | ||
Post-booster injection (day 223) | GMT | 44 (29–67) | 61 (39–95) | ||
Titer ≥40 | % | 62 (45–78) | 65 (44–83) | ||
SRH | n = 37 | n = 26 | |||
Post-second injection (day 43) | GMA | 15 (9.91–22) | 24 (16–36) | ||
Seroprotection rate | % | 57 (39–73) | 77 (56–91) | ||
Post-booster injection (day 223) | GMA | 24 (17–34) | 33 (23–48) | ||
Seroprotection rate | % | 78 (62–90) | 88 (70–98) |
Numbers in parenthesis are two-sided 95% confidence intervals; GMT/GMA, geometric mean titer/geometric mean area ;Seroprotection rate = SRH ≥25mm2 or MN ≥40.